drugset / Trial / NCT07095075
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
NaSequentialOpen-labelTreatment
Summary
This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-DKS1 in adult subjects with relapsed/refractory autoimmune diseases.
Timeline
- Start
- 2025-10-14
- Primary completion
- 2029-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUCAR-DKS1 NK cells | Cell therapy | 2.5e+07 cells/kg | — |
| Subject | LUCAR-DKS1 NK cells | Cell therapy | 5e+07 cells/kg | — |
| Subject | LUCAR-DKS1 NK cells | Cell therapy | 1e+08 cells/kg | — |
| Subject | LUCAR-DKS1 NK cells | Cell therapy | 2e+08 cells/kg | — |
| Subject | LUCAR-DKS1 NK cells | Cell therapy | 4e+08 cells/kg | — |
Indications
No indication recorded.